Skip to content

Endocrine · Reference monograph

Hypothalamic decapeptide that releases gonadotropins

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), the ten-residue peptide that hypothalamic neurons release into the pituitary portal circulation to control reproductive hormone output. Its structure, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, was worked out in the early 1970s by the laboratories of Andrew Schally and Roger Guillemin, work recognised with a share of the 1977 Nobel Prize in Physiology or Medicine. Because it is identical to the native hormone, gonadorelin has long served as a reference ligand in reproductive endocrinology.

Gonadorelin is an approved prescription product in several jurisdictions for specific diagnostic indications, notably assessment of pituitary gonadotroph reserve. In the laboratory it is central to one of endocrinology's best-known observations: the pituitary responds very differently to pulsatile versus continuous GnRH exposure. That finding shaped the development of long-acting GnRH agonists and antagonists and continues to inform research on puberty, hypothalamic amenorrhoea and the neural pulse generator. Gonadorelin is supplied here strictly as a research reference material.

Mechanism studied

  1. Gonadorelin
  2. Pituitary GnRH receptor
  3. LH & FSH
  4. Gonads

Gonadorelin binds the GnRH receptor (GnRHR), a class A G protein-coupled receptor on pituitary gonadotrophs that is unusual in lacking a cytoplasmic C-terminal tail. Receptor activation couples primarily to Gq/11, stimulating phospholipase C, inositol trisphosphate generation, intracellular calcium mobilisation and protein kinase C activity. These signals drive synthesis and release of luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn act on the gonads. Pulse frequency matters: faster pulses favour LH beta-subunit transcription, slower pulses favour FSH beta. Sustained, non-pulsatile exposure produces receptor desensitisation and uncoupling, suppressing gonadotropin output, a phenomenon studied extensively in pituitary cell and primate models.

Research highlights

  • 01Isolated and sequenced in 1971 from porcine and ovine hypothalami; Schally and Guillemin shared part of the 1977 Nobel Prize for hypothalamic hormone research.
  • 02Ernst Knobil's rhesus monkey experiments in the late 1970s showed that intermittent GnRH sustains gonadotropin secretion while continuous exposure suppresses it.
  • 03Pituitary desensitisation research with gonadorelin underpinned the design of later GnRH superagonists and antagonists.
  • 04Used as a stimulation reference in studies of delayed puberty, central precocious puberty and hypogonadotropic hypogonadism.
  • 05Open questions include how pulse frequency is decoded at the transcriptional level and how upstream kisspeptin neurons set the pulse generator.

Latest published research

36,900 papers on PubMed →

  1. Single-dose FSH protocol with 48- or 72-h coasting periods as simplified alternatives for in vitro embryo production in Angus oocyte donor cows

    Tríbulo P et al. · Theriogenology · 2027 Jan 1 · PMID 42815100

  2. Hormone-sparing non-surgical male contraception in dogs and cats: Current strategies and the emerging role of FSH receptor-targeted antibody fragments

    Navanukraw P et al. · Theriogenology · 2027 Jan 1 · PMID 42804870

  3. Deoxynivalenol exposure promotes apoptosis and disrupts GnRH-dependent LH production in pituitary gonadotrope-like cells

    Cai G et al. · Molecular and cellular endocrinology · 2027 Jan · PMID 42749249

  4. Stigmasterol alleviates central precocious puberty by targeting the IGF-1/PI3K/Akt/mTOR signaling pathway and modulating the Kisspeptin/GnRH axis

    Dong L et al. · Biochimica et biophysica acta. Molecular basis of disease · 2027 Jan · PMID 42562054

  5. Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche

    Banerjee AA et al. · Clinica chimica acta; international journal of clinical chemistry · 2027 Jan 1 · PMID 42364891

  6. Statement of Retraction: The effect of adding L-Carnitin to the GnRH-antagonist protocol on assisted reproductive technology outcome in women with polycystic ovarian syndrome: A randomized clinical trial

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2026 Dec 31 · PMID 42885620

  7. Restoring ovulation in functional hypothalamic amenorrhea: impact of polycystic ovarian morphology on hormonal response to pulsatile GnRH

    Boegl M et al. · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2026 Dec 31 · PMID 42176250

  8. Protocol flexibility in PCOS: a combination of controlled ovarian stimulation and endometrial preparation strategies shows no impact on live birth outcomes after frozen embryo transfer-a retrospective cohort study

    Chen D et al. · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2026 Dec 31 · PMID 41934169

Live feed from PubMed (NCBI) for “Gonadorelin (GnRH)”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Registered studies

1,544 on ClinicalTrials.gov →

From the public ClinicalTrials.gov registry for “Gonadorelin (GnRH)”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.

Key references

  1. [1]Manufacturer's prescribing information — FDA / EMA / ANVISA
  2. [2]PubMed — reviews on gonadorelin and stimulation tests

FAQ

  • Yes. Gonadorelin has the same ten-amino-acid sequence as mammalian GnRH-I, including the N-terminal pyroglutamate and C-terminal glycinamide. This identity is why it is used as a reference ligand, whereas analogues such as leuprorelin or triptorelin carry substitutions that alter stability and receptor kinetics.

  • Pituitary gonadotrophs are tuned to intermittent signals. Pulsatile GnRH maintains LH and FSH secretion, while continuous exposure leads to receptor desensitisation and suppression. This dual behaviour is a foundational concept in reproductive endocrinology and explains why research designs carefully control the timing of exposure.

  • The World Anti-Doping Agency lists GnRH and its analogues under section S2 (peptide hormones, growth factors and related substances), prohibited in males because they can raise testosterone. Researchers in sports science should consult the current WADA Prohibited List.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp